SCYX (SCYNEXIS) Price-to-Funds-From-Operations: (As of Sep. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SCYX SCYNEXIS Inc SCYX
34 GF Score
Price $4.60
GF Value $17.62
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is SCYNEXIS Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.

SCYX
34GF Score
SCYNEXIS Inc SCYX
Price-to-Funds-From-Operations is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is SCYNEXIS (SCYX) Overvalued in 2026?

Based on GuruFocus' analysis, SCYNEXIS stock appears to be undervalued. The current stock price of $4.60 is trading 73.9% below its estimated GF Value™ of $17.62. GuruFocus considers SCYNEXIS to be Possible Value Trap.

Key valuation signals for SCYX:

  • Price-to-Funds-From-Operations:
  • GF Value™: $17.62 vs. price of $4.60 (73.9% below fair value)
  • GF Score™: 34/100 with 3 warning signs

No single metric tells the full story. See the SCYX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SCYNEXIS Business Description

Other Exchanges 0L49:UK135:Germany
Address 1 Evertrust Plaza, 13th Floor, Jersey City, NJ, USA, 07302 - 6548
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
34GF Score

Get the complete analysis for SCYX

Price-to-Funds-From-Operations is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.60
Price
$17.62
GF Value